Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth

Core Viewpoint - The article emphasizes the positive outlook for Ionis Pharmaceuticals (IONS) following recent approvals and upcoming catalysts that are expected to drive strong upside potential for the company [1]. Group 1 - The author has been focusing on Ionis for over five years, particularly in the healthcare sector, and shares insights from decades of investment experience [1]. - The article is the 13th in a series discussing Ionis, indicating a sustained interest and analysis of the company's performance and prospects [1]. Group 2 - The author expresses a beneficial long position in Ionis shares, indicating confidence in the company's future performance [2]. - There is a mention of potential trading activity in Ionis shares within the next 72 hours, suggesting ongoing engagement with the stock [2].